179 related articles for article (PubMed ID: 29980706)
1. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.
Shirakashi M; Yoshifuji H; Kodama Y; Chiba T; Yamamoto M; Takahashi H; Uchida K; Okazaki K; Ito T; Kawa S; Yamada K; Kawano M; Hirata S; Tanaka Y; Moriyama M; Nakamura S; Kamisawa T; Matsui S; Tsuboi H; Sumida T; Shibata M; Goto H; Sato Y; Yoshino T; Mimori T
Sci Rep; 2018 Jul; 8(1):10262. PubMed ID: 29980706
[TBL] [Abstract][Full Text] [Related]
2. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Wang L; Zhang P; Wang M; Feng R; Lai Y; Peng L; Fei Y; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W
Arthritis Res Ther; 2018 Apr; 20(1):65. PubMed ID: 29636109
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
An W; Wu Z; Li M; Yu H; Zhao X; Wang X; Wang Y; Wang Q; Duan W; Kong Y; Ma H; Ou X; You H; Liu Y; Li P; Duan T; Jia J
Orphanet J Rare Dis; 2022 Aug; 17(1):307. PubMed ID: 35927746
[TBL] [Abstract][Full Text] [Related]
5. Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse.
Lanzillotta M; Della-Torre E; Milani R; Bozzolo E; Bozzalla-Cassione E; Rovati L; Arcidiacono PG; Partelli S; Falconi M; Ciceri F; Dagna L
Arthritis Res Ther; 2018 Oct; 20(1):222. PubMed ID: 30285841
[TBL] [Abstract][Full Text] [Related]
6. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines.
Yoshifuji H; Umehara H
Mod Rheumatol; 2023 Mar; 33(2):252-257. PubMed ID: 35993488
[TBL] [Abstract][Full Text] [Related]
10. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
[TBL] [Abstract][Full Text] [Related]
11. HLA-DRB1 Is Associated with Therapeutic Responsiveness in IgG4-related Disease.
Yamamoto M; Tanaka T; Aochi S; Uehara M
Intern Med; 2024 Jan; 63(2):207-211. PubMed ID: 37225483
[TBL] [Abstract][Full Text] [Related]
12. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Liu Y; Zeng Q; Zhu L; Gao J; Wang Z; Wang Z; Yang F; Wang K; Chen D; Xia C; Zhang S; Wang Y; Shen D; Yu G; Li ZG
Rheumatology (Oxford); 2020 Aug; 59(8):2115-2123. PubMed ID: 32097488
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report.
Otani T; Iwamoto H; Yoshida Y; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hirata S; Sugiyama E; Hattori N
J Asthma; 2022 Dec; 59(12):2395-2401. PubMed ID: 34937495
[No Abstract] [Full Text] [Related]
14. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients.
Miki M; Fujimori N; Oono T; Kawabe K; Ohno A; Matsumoto K; Teramatsu K; Tachibana Y; Ogawa Y
J Dig Dis; 2019 Mar; 20(3):152-158. PubMed ID: 30701685
[TBL] [Abstract][Full Text] [Related]
15. Different factors underlie recurrent and de novo organ involvement in immunoglobulin G4-related disease.
Mizushima I; Tsuge S; Fujisawa Y; Hara S; Suzuki F; Ito K; Fujii H; Yamada K; Kawano M
Rheumatology (Oxford); 2020 Mar; 59(3):513-518. PubMed ID: 31373632
[TBL] [Abstract][Full Text] [Related]
16. Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study.
Fukui S; Nakai T; Kawaai S; Ikeda Y; Suda M; Nomura A; Tamaki H; Kishimoto M; Ohde S; Okada M
Medicine (Baltimore); 2022 Sep; 101(39):e30932. PubMed ID: 36181016
[TBL] [Abstract][Full Text] [Related]
17. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment.
Yamamoto M; Nojima M; Takahashi H; Yokoyama Y; Ishigami K; Yajima H; Shimizu Y; Tabeya T; Matsui M; Suzuki C; Naishiro Y; Takano K; Himi T; Imai K; Shinomura Y
Rheumatology (Oxford); 2015 Jan; 54(1):45-9. PubMed ID: 24907151
[TBL] [Abstract][Full Text] [Related]
18. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Dong C; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Semin Arthritis Rheum; 2020 Dec; 50(6):1513-1520. PubMed ID: 32113839
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Clin Rheumatol; 2023 Jan; 42(1):135-143. PubMed ID: 36074221
[TBL] [Abstract][Full Text] [Related]
20. IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy.
Poo SX; Tham CSW; Smith C; Lee J; Cairns T; Galliford J; Hamdulay S; Jacyna M; Levy JB; McAdoo SP; Roufosse C; Wernig F; Mason JC; Pusey CD; Tam FWK; Tomlinson JAP
QJM; 2019 Oct; 112(10):763-769. PubMed ID: 31225617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
